Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.
Published
Journal Article (Review)
Diabetic macular oedema is the most common cause of diabetic retinopathy-induced vision loss. Efficacy of anti-vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. An Asian-specific guideline for diabetic macular oedema treatment is needed as patients in Asia tend to present with far more advanced disease than seen elsewhere in the world. Previous reviews of diabetic macular oedema management lacked a broader assessment of anti-vascular endothelial growth factor treatment choices and newer trials. Recent clinical trial data allow head-to-head comparisons between the different anti-vascular endothelial growth factor agents and treatment regimens. This review aims to summarize the clinical evidence related to various treatment regimens for clinicians, with a focus on anti-vascular endothelial growth factor therapies, and to provide guidance on the treatment of diabetic macular oedema in Asian patients.
Full Text
Duke Authors
Cited Authors
- Cheung, GC; Yoon, YH; Chen, LJ; Chen, SJ; George, TM; Lai, TY; Park, KH; Tahija, SG; Uy, HS; Wong, TY
Published Date
- January 2018
Published In
Volume / Issue
- 46 / 1
Start / End Page
- 75 - 86
PubMed ID
- 28558152
Pubmed Central ID
- 28558152
Electronic International Standard Serial Number (EISSN)
- 1442-9071
Digital Object Identifier (DOI)
- 10.1111/ceo.12999
Language
- eng
Conference Location
- Australia